---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-113410"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T01:58:07.431746+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q3 2023: GSK royalties $57M, net income $82M, launches XACDURO, positive Phase 3 zoliflodacin

## Summary
- GSK royalty revenue $57.0M (Q3 2023) vs $65.6M (Q3 2022); net product sales $13.7M.
- Net income $82.0M ($1.26 basic EPS) vs $265.5M ($3.81) in Q3 2022; prior year included gain on sale.
- Launched XACDURO for Acinetobacter HABP/VABP; announced positive Phase 3 zoliflodacin for gonorrhea.
- Appointed Stephen Basso as CFO; repurchased $11.0M of stock in Q3.
- Cash $180.0M; invested $25M in Armata Pharmaceuticals.

## SEC filing metadata
- accession: 0001104659-23-113410
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/0001104659-23-113410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/tm2329306d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-113410
- JSON: https://secwatch.observer/filing/0001104659-23-113410.json
- Plain text: https://secwatch.observer/filing/0001104659-23-113410.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported the third quarter ended September 30, 2023 results: net income $82.0 million, EPS $1.26 basic per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $82.0 million
  - EPS: $1.26 basic per share
  - Result: reported results
  source text: On November 1, 2023, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923113410/0001104659-23-113410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.